ClinicalTrials.gg

Program

bremelanotide

Also written as “Bremelanotide” and “Vyleesi (Bremelanotide Injection)”.

Its studies are mostly in Sexual Dysfunctions, Psychological · Obesity · Kidney Diseases, led by 3 companies.

Furthest: phase 4, since Dec 28, 20148 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Palatin Technologies61 open or runningphase 3since Dec 28, 2014Jan 18, 2007none ahead
Cosette Pharmaceuticals10 open or runningphase 4since Feb 19, 2025Feb 19, 2025none ahead
Kwang Dong Pharmaceutical10 open or runningphase 3since Jun 10, 2021Jun 10, 2021none ahead

Also a collaborator on its studies: Azurity Pharmaceuticals and king-pharmaceuticals-is-now-a-wholly-owned-subsidiary-of-pfi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 18, 2007First study: phase 2 study in Sexual Dysfunctions, PsychologicalNew to Palatin TechnologiesPalatin Technologies · NCT00425256 · United States
  2. Jun 24, 2011Phase 2 study in Sexual Dysfunctions, PsychologicalPalatin Technologies · NCT01382719 · 612 enrolled · United States, Canada
  3. Dec 28, 2014Phase 3 study in Sexual Dysfunctions, PsychologicalPalatin Technologies · NCT02333071 · 723 enrolled · United States, Canada
  4. Jan 12, 2015Phase 3 study in Sexual Dysfunctions, PsychologicalPalatin Technologies · NCT02338960 · 714 enrolled · United States, Canada
  5. Jun 10, 2021Kwang Dong Pharmaceutical's first study: phase 3 study in Sexual Dysfunctions, PsychologicalNew to Kwang Dong PharmaceuticalKwang Dong Pharmaceutical · NCT04943068 · 193 enrolled · Korea, Republic of
  6. Jan 6, 2023Phase 2 study in Kidney DiseasesPalatin Technologies · NCT05709444 · 16 enrolled · United States
  7. Jun 5, 2024Phase 2 study in ObesityPalatin Technologies · NCT06565611 · 108 enrolled · United States
  8. Feb 19, 2025Cosette Pharmaceuticals's first study: phase 4 study in Lactating MotherNew to Cosette PharmaceuticalsCosette Pharmaceuticals · NCT06867835 · 10 enrolled · United States

TargetBeta

MC4R →read by rule
“Melanocortin receptor 4 agonist; Melanocortin receptor 4 agonist”ChEMBL 37, by rule

Other programs on MC4R

ProgramCompanyFurthest phaseStudies
setmelanotideruleRhythm Pharmaceuticalsphase 422
bivamelagonruleRhythm Pharmaceuticalsphase 23
mifomelatideruleendevica-biophase 22

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06867835Lactating Mother · United States4CompletedCosette PharmaceuticalsNov 15, 202510
NCT06565611Obesity · United States2Active, not recruitingPalatin TechnologiesFeb 5, 2025108
NCT05709444Kidney Diseases · United States2CompletedPalatin TechnologiesApr 26, 202416
NCT04943068Sexual Dysfunctions, Psychological · Korea, Republic of3CompletedKwang Dong PharmaceuticalMay 16, 2023193
NCT02338960Sexual Dysfunctions, Psychological · United States, Canada3CompletedPalatin TechnologiesAug 2016714
NCT02333071Sexual Dysfunctions, Psychological · United States, Canada3CompletedPalatin TechnologiesJul 2016723
NCT01382719Sexual Dysfunctions, Psychological · United States, Canada2CompletedPalatin TechnologiesSep 2012612
NCT00425256Sexual Dysfunctions, Psychological · United States2CompletedPalatin TechnologiesMay 2007

How it is read

Names in the registry

  • “Bremelanotide”, 5 entries
  • “bremelanotide”, 2 entries
  • “Vyleesi (Bremelanotide Injection)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.